Literature DB >> 23097521

Assessment and management of psoriasis: summary of NICE guidance.

Eleanor Samarasekera1, Laura Sawyer, Jill Parnham, Catherine H Smith.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23097521     DOI： 10.1136/bmj.e6712

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic.

Authors:  Michele Maria Luchetti; Devis Benfaremo; Anna Campanati; Elisa Molinelli; Monia Ciferri; Serena Cataldi; William Capeci; Marco Di Carlo; Anna Maria Offidani; Fausto Salaffi; Armando Gabrielli
Journal:  Clin Rheumatol       Date:  2018-07-29       Impact factor: 2.980

2.  Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.

Authors:  Catherine Queille-Roussel; Martin Olesen; John Villumsen; Jean-Philippe Lacour
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

3.  Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis.

Authors:  Juan Ruano; Beatriz Isla-Tejera; Rafael Jiménez-Puya; Ana Rodriguez-Martin; Manuel Cárdenas; Francisco Gómez; A Antonio Vélez; José R Del Prado-Llergo; José C Moreno-Giménez
Journal:  Dermatol Ther (Heidelb)       Date:  2013-07-06

Review 4.  The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge.

Authors:  Magdalena Czarnecka-Operacz; Anna Sadowska-Przytocka
Journal:  Postepy Dermatol Alergol       Date:  2014-12-03       Impact factor: 1.837

5.  Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.

Authors:  Vassilis Fragoulakis; Efklidis Raptis; Elli Vitsou; Nikolaos Maniadakis
Journal:  Clinicoecon Outcomes Res       Date:  2015-01-08

6.  Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.

Authors:  C Queille-Roussel; B Bang; F Clonier; J-P Lacour
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-15       Impact factor: 6.166

Review 7.  A clinical review of phototherapy for psoriasis.

Authors:  Ping Zhang; Mei X Wu
Journal:  Lasers Med Sci       Date:  2017-10-24       Impact factor: 3.161

8.  Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.

Authors:  Carle Paul; Craig Leonardi; Alan Menter; Kristian Reich; Linda Stein Gold; Richard B Warren; Anders Møller; Mark Lebwohl
Journal:  Am J Clin Dermatol       Date:  2017-06       Impact factor: 7.403

9.  Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.

Authors:  Catherine Queille-Roussel; Monika Rosen; Fabrice Clonier; Kasper Nørremark; Jean-Philippe Lacour
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

10.  Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.

Authors:  John Koo; Stephen Tyring; William P Werschler; Suzanne Bruce; Martin Olesen; John Villumsen; Jerry Bagel
Journal:  J Dermatolog Treat       Date:  2015-10-07       Impact factor: 3.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.